BCMA x CD3 T-cell engager in a patient with penta-refractory multiple myeloma and HIV: a clinical and immunological report

被引：0
|
作者：
Cords, Leon [1 ]
Schaefers, Christoph [2 ]
Kamili, Abdulaziz [2 ]
Hoffmann, Christian [3 ,4 ]
Cichutek, Sophia [2 ]
Haag, Friedrich [5 ]
Polywka, Susanne [6 ]
Bokemeyer, Carsten [2 ]
Leypoldt, Lisa [2 ]
Alsdorf, Winfried [2 ]
zur Wiesch, Julian Schulze [1 ,7 ]
Weisel, Katja C. [2 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Med 1, Infect Dis Unit, Hamburg, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Hematol Oncol & Bone Marrow Transplantat, Sect Pneumol, Hamburg, Germany
[3] ICH Study Ctr, Hamburg, Germany
[4] Univ Hosp Schleswig Holstein, Dept Internal Med 2, Campus Kiel, Kiel, Germany
[5] Univ Med Ctr Hamburg Eppendorf, Inst Immunol, Hamburg, Germany
[6] Univ Med Ctr Hamburg Eppendorf, Inst Med Microbiol Virol & Hyg, Hamburg, Germany
[7] German Ctr Infect Res DZIF, Partner Site Hamburg Lubeck Borstel Riems, Hamburg, Germany
来源：
HAEMATOLOGICA | 2024年 / 109卷 / 09期
基金：
欧盟地平线“2020”;
关键词：
D O I：
10.3324/haematol.2023.284917
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3071 / 3077
页数：7
相关论文
共 50 条
  • [21] Brief report:: Inherited and somatic CD3ζ mutations in a patient with T-cell deficiency
    Rieux-Laucat, F
    Hivroz, C
    Lim, A
    Mateo, V
    Pellier, I
    Selz, F
    Fischer, A
    Le Deist, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (18): : 1913 - 1921
  • [22] Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
    Vij, Ravi
    Kumar, Shaji Kunnathu
    D'Souza, Anita
    Mckay, John T.
    Voorhees, Peter M.
    Chung, Alfred
    Tuchman, Sascha Alexander
    Korde, Neha
    Weisel, Katja
    Teipel, Raphael
    Bueno, Orlando
    Feng, Zhongling
    Rosenberg, Tanya S.
    Pothacamury, Rajvineeth Kumar
    Polepally, Akshanth R.
    Lee, Shane
    Jin, Ziyi
    Ross, Jeremy A.
    Ahsan, Aarif
    Talati, Chetasi
    Rodriguez, Cesar
    BLOOD, 2023, 142
  • [23] Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    Adegbite, Benjamin O.
    Tan, Carlyn Rose
    Shekarkhand, Tala
    Firestone, Ross S.
    Jurgens, Eric M.
    Miller, Kevin
    Lesokhin, Alexander M.
    Shah, Gunjan L.
    Korde, Neha
    Rajeeve, Sridevi
    Chung, David J.
    Landau, Heather J.
    Scordo, Michael
    Hassoun, Hani
    Maclachlan, Kylee H.
    Shah, Urvi A.
    Hultcrantz, Malin
    Hamadeh, Issam S.
    Giralt, Sergio
    Mailankody, Sham
    Usmani, Saad Z.
    Hashmi, Hamza
    BLOOD, 2024, 144 : 4735 - 4736
  • [24] Recent updates on bispecific T-cell engager (BiTE) antibodies in relapsed and refractory multiple myeloma.
    Rafae, Abdul
    Wahab, Ahsan
    Ehsan, Hamid
    Christy, Joshua
    Saleem, Tabinda
    Kandah, Emad
    Ali, Rabia
    Malik, Mustafa Nadeem
    Ali, Sundas
    Saeed, Sara
    Anwer, Faiz
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma
    Grab, Anna
    Kim, Peter
    Bisht, Kamlesh
    Wang, Hongfang
    Vandevelde, Halgi
    John, Lukas
    Shome, Debarati
    Sarka, Irene
    Weinhold, Niels
    Raab, Marc
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S182 - S183
  • [26] Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
    Krishnan, Amrita Y.
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Karlin, Lionel
    Benboubker, Lotfi
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Garfall, Alfred L.
    Usmani, Saad Z.
    Mateos, Maria-Victoria
    Nahi, Hareth
    van de Donk, Niels W. C. J.
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Rosinol, Laura
    Chari, Ajai
    Bhutani, Manisha
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Stephenson, Tara
    Goldberg, Jenna D.
    Banerjee, Arnob
    Krishnan, Amrita
    BLOOD, 2020, 136
  • [28] Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy
    Kambhampati, Swetha
    Sheng, Ying
    Huang, Chiung-Yu
    Bylsma, Sophia
    Lo, Mimi
    Kennedy, Vanessa
    Natsuhara, Kelsey
    Martin, Thomas
    Wolf, Jeffrey
    Shah, Nina
    Wong, Sandy W.
    BLOOD ADVANCES, 2022, 6 (07) : 2045 - 2054
  • [29] Clinical responses and pharmacokinetics of fully human BCMA targeting CAR T-cell therapy in relapsed/refractory multiple myeloma.
    Li, Chunrui
    Zhou, Jianfeng
    Wang, Jue
    Hu, Guang
    Du, Aihua
    Zhou, Xiaoxi
    Meng, Li
    Hong, Zhenya
    Chen, Liting
    Mao, Xia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Disparities in access and practice patterns of BCMA-directed T-cell engager (TCE) therapies in multiple myeloma: a global perspective
    Hassan, Hamza
    Samur, Mehmet
    Cohen, Adam
    Einsele, Hermann
    Moreau, Philippe
    San-Miguel, Jesus
    Kumar, Shaji
    Mateos, Maria-Victoria
    Avigan, David
    Berdeja, Jesus
    Chari, Ajai
    Sonneveld, Pieter
    Gay, Francesca
    Krishnan, Amrita
    Usmani, Saad
    Jagannath, Sundar
    Laubach, Jacob
    Mo, Clifton
    Sperling, Adam
    Nadeem, Omar
    Ghobrial, Irene
    Richardson, Paul
    Anderson, Kenneth
    Munshi, Nikhil
    Midha, Shonali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S41 - S42
12345